Supplements keep H&H pet sales resilient in Q1: full analysis
Health and Happiness Group opened fiscal 2026 with a split picture in pet. Its Pet Nutrition and Care segment posted a 1.5% year-over-year revenue decline in Q1, ending March 31, 2026, to RMB 493.4 million, but supplements again outperformed the rest of the portfolio. H&H said Zesty Paws grew 15.5% on a like-for-like basis, helping offset pressure tied to a supply chain transition in Mainland China. The company’s message to investors was clear: supplements remain the core growth lever in pet, especially in North America. (globalpetindustry.com)
That performance fits H&H’s recent trajectory. In its March 3, 2026 operational update for the full year 2025, the company said its Pet Nutrition and Care business delivered high-single-digit like-for-like growth, with high-margin pet supplements growing at a mid-teens rate. H&H linked that momentum to long-running pet premiumization and humanization trends, themes that continue to shape both consumer demand and capital allocation across the category. Zesty Paws has been central to that strategy since H&H acquired the brand in 2021, following its earlier move into pet nutrition with Solid Gold. (www1.hkexnews.hk)
The weak spot in Q1 was not supplements, but operating disruption. According to GlobalPETS, H&H attributed the segment decline to a supply chain transition in Mainland China intended to mitigate tariff and inflation impacts. The company also said Solid Gold has undergone premiumization and restructuring in China, part of a broader effort to optimize channels and improve the mix toward higher-margin products. In prior disclosures, H&H has separated pet supplements from “other” pet products, with supplements carrying a meaningfully stronger growth profile than pet food. (globalpetindustry.com)
There’s also a veterinary angle that makes this earnings update more relevant than a standard consumer packaged goods story. In January 2026, Zesty Paws launched Zesty Paws Professional, its first line built specifically for veterinary recommendation, with products targeting digestive health and healthy aging in dogs. H&H said the line would be distributed through epiq Animal Health, while market reporting also points to Durvet distribution support. That move suggests H&H is trying to turn retail supplement brand equity into clinic-level credibility and recommendation. (prnewswire.com)
Industry commentary suggests the company is betting into a still-expanding category. PetfoodIndustry reported last month that experts see double-digit growth potential in pet supplements, with probiotics and mobility support among the most common use cases, and with omnichannel distribution becoming increasingly important. Veterinary Practice News, meanwhile, noted that practitioners are seeing more patients already receiving multiple supplements, often without clear veterinary guidance, creating a gap between consumer marketing and scientific validation. (petfoodindustry.com)
Why it matters: For veterinary teams, H&H’s quarter is less about one company’s sales line and more about where client demand is headed. As supplement brands expand into veterinary distribution, practices may face more questions from pet parents about efficacy, safety, ingredient quality, and product selection. That’s especially important in a category where regulation is different from human supplements and many products are marketed without FDA approval for veterinary use. AVMA states that the Dietary Supplement Health and Education Act applies to humans, not animals, and Merck Veterinary Manual similarly notes that veterinary nutraceuticals are not FDA approved, even as use is widespread. In practice, that leaves veterinarians in the role of translator, helping pet parents sort promising adjunctive options from products with limited evidence or unclear quality controls. (avma.org)
The commercial takeaway is that supplement demand appears resilient, even when broader pet portfolios are under pressure from sourcing changes, inflation, or channel resets. For clinics, that may create opportunities around evidence-based recommendations, especially in digestive health, mobility, and healthy aging, but it also raises the bar for staff education and product review. Brands that can pair consumer awareness with stronger veterinary relationships may gain share, though sustained success in clinics will depend on more than retail momentum. (globalpetindustry.com)
What to watch: The next signal will be whether H&H’s China supply chain transition eases enough for overall pet segment growth to reaccelerate, and whether Zesty Paws Professional can gain meaningful adoption in veterinary practices during the rest of 2026. If supplement growth keeps outpacing the broader segment, H&H may deepen its push into clinic-recommended, higher-margin wellness products. (globalpetindustry.com)